Different age groups may get different Covid vaccines, experts say

Oxford/AstraZeneca planning new trial of lower-dose jab to see how well it works in older people

Concerns around the efficacy of the Oxford University/AstraZeneca coronavirus jab in older people could lead to different age groups being given different vaccines, experts have said.

The partners announced last week that the vaccine had a 70% efficacy overall. For most trial participants – given two full doses, spaced a month apart – the efficacy was 62%, but for 3,000 participants mistakenly given half a dose for their first jab, the efficacy was 90%. No participants, regardless of dosing, developed severe Covid or were hospitalised with the disease.

Continue reading...

Families bereaved by Covid say UK plan to allow Christmas mixing is ‘sheer madness’

Support group warns that large gatherings are too risky and calls for low-key festive period

People bereaved by Covid-19 have warned that allowing families in the UK to get together over Christmas is “sheer madness” and urged the public to have a low-key festive period rather than risk the grief they have endured.

Members of the Covid-19 Bereaved Families for Justice group told the Guardian that large family gatherings were too high-risk, with one grieving husband saying anyone prepared to mix family groups should also “prepare for a funeral”.

Continue reading...

A vaccine revolution | podcast

Results from clinical trials have shown that the world has three apparently highly effective vaccines for Covid-19. With the race now on for regulatory approval, production and distribution, is the end of the pandemic within reach?

After a gruelling year of successive waves of Covid-19 infections and national lockdowns there has been a burst of good news this month, with three separate vaccine candidates performing extremely well in clinical trials.

First, Pfizer and Moderna announced that their vaccines were testing at an efficacy of around 95%. Then came the news that the AstraZeneca vaccine (the one pre-ordered in bulk by the UK government) was hitting 90%. It marks not just a new phase in the Covid-19 pandemic but potentially a revolution in vaccine technology itself.

Continue reading...

Africa’s largest Covid treatment clinical trial launched by 13-country network

Anticov study with international research institutions aims to stop disease progression and protect fragile health systems

A network of 13 African countries has joined forces with global researchers to launch the largest clinical trial of potential Covid-19 treatments on the continent.

The Anticov study, involving Antwerp’s Institute of Tropical Medicine and international research institutions, aims to identify treatments that can be used to treat mild and moderate cases of Covid-19 early and prevent spikes in hospitalisation that could overwhelm fragile and already overburdened health systems in Africa.

Continue reading...

Coronavirus live news: Macron says worst of French second wave over; death tolls in Italy and Spain surge

French president says lockdown to ease; Italy reports most daily deaths since late March; Spain’s daily deaths highest of second wave

Scientists have warned the UK’s Christmas coronavirus plans, which will allow up to three households form a “bubble” to meet over the festive period, will cause the virus to spread and lead to further deaths.

Martin McKee, the professor of European public health at the London School of Hygiene and Tropical Medicine, said: “We know that the virus spreads easiest where people mix together, close to each other, for long periods of time indoors. These are exactly the conditions the government seems to be encouraging.”

Brazil registered a further 31,100 confirmed Covid-19 cases over the last 24 hours and 630 deaths, the health ministry said.

The South American nation has now registered 6,118,708 cases since the pandemic began and the official death toll has risen to 170,115, according to ministry data.

Continue reading...

Vaccine results bring us a step closer to ending Covid, says Oxford scientist

Latest breakthrough comes as PM says he hopes most at-risk could be immunised by Easter

The world is moving a step closer to ending the coronavirus pandemic, the scientist behind Britain’s first vaccine has declared, as Boris Johnson said he hoped the majority of those most at-risk could be immunised by Easter.

Successful trial results for the Oxford University/AstraZeneca vaccine, suggesting it could protect up to 90% of people, are the third set of promising findings in as many weeks. Before this year, there had never been a vaccine for a coronavirus.

Continue reading...

Oxford AstraZeneca vaccine to be sold to developing countries at cost price

Jab that is part of global initiative to distribute doses will remain at low price ‘in perpetuity’

The coronavirus vaccine produced by Oxford University and AstraZeneca will be available on a non-profit basis “in perpetuity” to low- and middle-income countries in the developing world.

The details of arrangements to supply poorer countries came as AstraZeneca revealed the interim results of a phase 3 trial of the vaccine, which is being heralded as the first to meet the more challenging requirements of the developing world.

Continue reading...

The Covid vaccine results are great news, but it’s not all over yet

Oxford/AstraZeneca findings have certain advantages over those from other versions

Within weeks, the prospects of an end to the pandemic have changed utterly, with three vaccines against Covid-19 reporting good results in final clinical trials and at least one likely to be used before Christmas. But there are still huge challenges ahead.

The results from the Oxford University/AstraZeneca vaccine, which is absolutely central to the UK’s vaccination strategy, may at first glance look not as good as those of Pfizer/BioNTech and Moderna – the two mRNA vaccines that have both reported 95% efficacy.

Continue reading...

US vaccine expert predicts life could be back to normal around May

Operation Warp Speed chief says if immunization plan goes well enough Americans should be vaccinated by May

As the number of Covid-19 cases in the United States passed 12 million, the Trump administration’s vaccine program adviser predicted that life in America could be back to normal around May of 2021 as immunization is set to begin.

The note of optimism came even as millions of Americans were expected to travel for the upcoming Thanksgiving holiday this week and many appeared to be ignoring warnings from health officials about furthering the spread of the infectious disease.

Continue reading...

France to ease Covid rules as Asian countries consider stricter action

WHO says Europe faces third wave early in 2021 if nations repeat their failures to prepare

France is preparing to ease its Covid-19 lockdown rules in the weeks leading up to Christmas with new daily caseloads falling and pressure building from retailers to allow the annual shopping season to go ahead.

But parts of east Asia that were thought to be controlling the disease have raised the possibility of new restrictions.

Continue reading...

Is this the beginning of an mRNA vaccine revolution? | Adam Finn

No one knew whether mRNA technology would work against this virus – but it does. It’s an extraordinary moment for science

The past few months have brought a number of scientific terms to public attention. We’ve had to digest R (a virus’s reproduction number) and PCR (the polymerase chain reaction method of testing). And now there’s mRNA. This last one has featured heavily in recent news reports because of the spectacular results of two new mRNA vaccines against coronavirus. It stands for “messenger ribonucleic acid”, a label familiar enough if you studied biology at O-level or GCSE, but otherwise hardly a household name. Even in the field of vaccine research, if you had said as recently as 10 years ago that you could protect people from infections by injecting them with mRNA, you would have provoked some puzzled looks.

Essentially, mRNA is a molecule used by living cells to turn the gene sequences in DNA into the proteins that are the building blocks of all their fundamental structures. A segment of DNA gets copied (“transcribed”) into a piece of mRNA, which in turn gets “read” by the cell’s tools for synthesising proteins. In the case of an mRNA vaccine, the virus’s mRNA is injected into the muscle, and our own cells then read it and synthesise the viral protein. The immune system reacts to these proteins – which can’t by themselves cause disease – just as if they’d been carried in on the whole virus. This generates a protective response that, we hope, lasts for some time. It’s so beautifully simple it almost seems like science fiction. But last week we learned that it was true.

Continue reading...

Why the race to find Covid-19 vaccines is far from over

Despite the promising news from Pfizer and Moderna, other efforts – which may be even more effective – continue around the world

While everyone celebrated this month’s news that not one but two experimental vaccines against Covid-19 have proved at least 90% effective at preventing disease in late-stage clinical trials, research into understanding how the Sars-CoV-2 virus, which causes Covid-19, interacts with the human immune system never paused.

There are plenty of questions still to answer about the Pfizer/BioNTech and Moderna vaccines: how well will they protect the elderly, for example, and how long for? Which aspects of the immune response that they elicit are protective and which aren’t? Can even better results be achieved, with vaccines that target different parts of the immune system?

Continue reading...

Michael J Fox: ‘Every step now is a frigging math problem, so I take it slow’

After living with Parkinson’s for 30 years, the actor still counts himself a lucky man. He reflects on what his diagnosis has taught him about hope, acting, family and medical breakthroughs

The last time I spoke to Michael J Fox, in 2013, in his office in New York, he was 90% optimistic and 10% pragmatic. The former I expected; the latter was a shock. Ever since 1998, when Fox went public with his diagnosis of early-onset Parkinson’s disease, he has made optimism his defining public characteristic, because of, rather than despite, his illness. He called his 2002 memoir Lucky Man, and he told interviewers that Parkinson’s is a gift, “albeit one that keeps on taking”.

During our interview, surrounded by the memorabilia (guitars, Golden Globes) he has accrued over the course of his career, he talked about how it had all been for the best. Parkinson’s, he said, had made him quit drinking, which in turn had probably saved his marriage. Being diagnosed at the heartbreakingly young age of 29 had also knocked the ego out of his career ambitions, so he could do smaller things he was proud of – Stuart Little, the TV sitcom Spin City – as opposed to the big 90s comedies, such as Doc Hollywood, that were too often a waste of his talents. To be honest, I didn’t entirely buy his tidy silver linings, but who was I to cast doubt on whatever perspective Fox had developed to make a monstrously unjust situation more bearable? So the sudden dose of pragmatism astonished me. Finding a cure for Parkinson’s, he said, “is not something that I view will happen in my lifetime”. Previously, he had talked about finding “a cure within a decade”. No more. “That’s just the way it goes,” he said quietly. It was like a dark cloud had partly obscured the sun.

Continue reading...

Covid vaccine technology pioneer: ‘I never doubted it would work’

Katalin Karikó’s mRNA research helped pave way for Pfizer/BioNTech and Moderna’s successful work

The Hungarian-born biochemist who helped pioneer the research behind the mRNA technology used in the two Covid-19 vaccines showing positive results believes it was always a no-brainer.

“I never doubted it would work,” Katalin Karikó told the Guardian. “I had seen the data from animal studies, and I was expecting it. I always wished that I would live long enough to see something that I’ve worked on be approved.”

Continue reading...

Scientists race to find ‘warm’ Covid vaccine to solve issue of cold storage

With potential injectable vaccines estimated to be out of reach for two-thirds of world’s population, scientists hope to find less-heat-sensitive formulations

News that one of the potential coronavirus vaccines had at least a 90% efficacy rate was a “victory for science”, said K Srinath Reddy, a cardiologist and president of the Public Health Foundation of India. But it meant little to his country’s 1.3 billion citizens.

“For us, the Pfizer vaccine is more of a scientific curiosity than a practical possibility,” Reddy said.

Continue reading...

Coronavirus is evolving. Whether it gets deadlier or not may depend on us | Laura Spinney

There’s now evidence that ignoring social distancing rules could help more lethal strains of Covid-19 to win out

Letting the virus that causes Covid-19 circulate more-or-less freely is dangerous not only because it risks overwhelming hospitals and so endangering lives unnecessarily, but also because it could delay the evolution of the virus to a more benign form and potentially even make it more lethal.

Though the data is still sketchy and the measures crude, this effect may already be influencing the difference in death rates between Sweden – which took a relaxed approach to containment until recently – and Norway, whose measures have been much stricter. Sweden has more than three times as many deaths per 100 cases as its neighbour.

Continue reading...

Covid-19 antibodies reduce faster in men than women – study

Finding has implications for one-size-fits-all approach to vaccine development

Antibody levels against the virus that causes Covid-19 appear to fall faster in men than in women, a study suggests – a finding that could have implications for vaccine research.

Historically, medical research has often taken a one-size-fits-all approach, lumping women and men together despite growing evidence that the sexes differ in how they catch and fight disease. Covid-19 seems to be a case in point, with women more likely to be infected but men thought to be up to twice as likely to die from the virus.

Continue reading...

Dolly Parton partly funded Moderna Covid vaccine research

The country music icon’s $1m donation supported the latest breakthrough by Moderna and several research papers

It’s truly the greatest gift of all: a $1m donation by Dolly Parton to coronavirus vaccine research supported the development of the Moderna vaccine, which shows 95% protection from the virus.

In April, Parton donated £800,000 to research after her friend Dr Naji Abumrad of the Vanderbilt Institute for Infection, Immunology and Inflammation at Vanderbilt University in Tennessee told her that they were making “some exciting advancements” in the search for a cure for the virus. Abumrad and Parton became friends in 2014 after the singer was involved in a car accident and treated at Vanderbilt.

Continue reading...

Covid: chemicals found in everyday products could hinder vaccine

Researchers worry PFAS, commonly found in the bodies of Americans, will reduce the immunization’s effectiveness

The successful uptake of any vaccine for Covid-19, a crucial step in returning a sense of normalcy after a year ravaged by the coronavirus pandemic, could be hindered by widespread contamination from a range of chemicals used in everyday products.

Small amounts of per- and polyfluoroalkyl (or PFAS) chemicals are commonly found in the bodies of people in the US, as well as several other countries. These man-made chemicals, used in everything from non-stick pans to waterproof clothes to pizza boxes, have been linked to an elevated risk of liver damage, decreased fertility and even cancer.

Continue reading...

Researchers confirm human-to-human transmission of rare virus in Bolivia

Chapare virus, which causes haemorrhagic fevers, was transmitted to health workers in La Paz and resulted in three deaths

Researchers with the US Centers for Disease Control and Prevention have discovered human-to-human transmission of a rare virus in Bolivia belonging to a family of viruses that can cause haemorrhagic fevers, such as Ebola.

The news is a reminder that scientists are working to identify new viral threats to humankind, even as countries around the world battle a new wave of Covid-19 outbreaks.

Continue reading...